87 related articles for article (PubMed ID: 15732779)
1. [Is syndecan-1 an independent prognostic factor in patients with laryngeal carcinoma?].
Klatka J; Skomra D; Paduch R; Kupisz K; Tryka E; Harytanowicz M; Kłos A
Otolaryngol Pol; 2004; 58(5):933-40. PubMed ID: 15732779
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 expression in laryngeal cancer.
Klatka J
Eur Arch Otorhinolaryngol; 2002 Mar; 259(3):115-8. PubMed ID: 12003262
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
4. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
Lundin M; Nordling S; Lundin J; Isola J; Wiksten JP; Haglund C
Oncology; 2005; 68(4-6):306-13. PubMed ID: 16020957
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
[TBL] [Abstract][Full Text] [Related]
6. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis.
Chen CL; Ou DL
Hum Pathol; 2006 Oct; 37(10):1279-85. PubMed ID: 16949936
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1: a new prognostic marker in laryngeal cancer.
Pulkkinen JO; Penttinen M; Jalkanen M; Klemi P; Grénman R
Acta Otolaryngol; 1997 Mar; 117(2):312-5. PubMed ID: 9105473
[TBL] [Abstract][Full Text] [Related]
8. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
9. A prognostic value of syndecan-1 in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
11. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of prognostic value of some antigens: p53, bcl-2 and syndecan-1 in laryngeal cancer as well as determination of the usefulness of these antigens in presenting response to cisplatinum in primary cellular cultures of laryngeal cancer].
Klatka J
Otolaryngol Pol; 2003; 57(5):765-8. PubMed ID: 14994627
[No Abstract] [Full Text] [Related]
13. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
Fujiya M; Watari J; Ashida T; Honda M; Tanabe H; Fujiki T; Saitoh Y; Kohgo Y
Jpn J Cancer Res; 2001 Oct; 92(10):1074-81. PubMed ID: 11676858
[TBL] [Abstract][Full Text] [Related]
14. [The expression of cell adhesion molecule Syndecan-1 and E-candherin in laryngeal cancer].
Li Y; Yang C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Dec; 17(12):736-8. PubMed ID: 15017723
[TBL] [Abstract][Full Text] [Related]
15. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J; Kallajoki M; Kujala I; Matikainen MT; Alanen K; Jalkanen M; Salmivirta M
APMIS; 2004 Feb; 112(2):89-97. PubMed ID: 15056224
[TBL] [Abstract][Full Text] [Related]
17. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
Lovell R; Dunn JA; Begum G; Barth NJ; Plant T; Moss PA; Drayson MT; Pratt G;
Br J Haematol; 2005 Aug; 130(4):542-8. PubMed ID: 16098068
[TBL] [Abstract][Full Text] [Related]
18. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Lundin M; Kokkola A; von Boguslawski K; Haglund C
Int J Cancer; 2001 Jan; 95(1):1-6. PubMed ID: 11241302
[TBL] [Abstract][Full Text] [Related]
19. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of syndecan-1 expression in human endometrial cancer.
Hasengaowa ; Kodama J; Kusumoto T; Shinyo Y; Seki N; Hiramatsu Y
Ann Oncol; 2005 Jul; 16(7):1109-15. PubMed ID: 15851381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
